Abstract
Incremental, symptom-limited CPET is safe in patients with suspected or confirmed pulmonary hypertension. In over 3800 tests, no deaths or syncopal events occurred, with an adverse event rate of only 0.05%, supporting wider use under proper supervision. https://bit.ly/4qdZf6x